This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

To Compare the Efficacy and Safety of a Therapy of Tacrolimus With Sirolimus or MMF in Kidney Transplantation. (RESTORE)

This study has been completed.
Information provided by (Responsible Party):
Astellas Pharma Inc Identifier:
First received: February 23, 2006
Last updated: August 28, 2014
Last verified: August 2014
Primary objective of this study is to compare the two therapy regimens with regard to renal function by using calculated creatinine clearance. The secondary objectives are to compare the efficacy and safety profiles of the two therapy regimens.

Condition Intervention Phase
Kidney Transplantation Drug: Tacrolimus Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Multicentre, Randomised, Open Clinical Study to Compare the Efficacy and Safety of a Combination Therapy of Tacrolimus With Sirolimus Versus Tacrolimus With Mycophenolate Mofetil in Kidney Transplantation.

Resource links provided by NLM:

Further study details as provided by Astellas Pharma Inc:

Primary Outcome Measures:
  • Renal function as assessed by calculated creatinine clearance at month 6. [ Time Frame: 6 months ]

Secondary Outcome Measures:
  • Acute rejection: Incidence of and time to first acute rejection [ Time Frame: 6 months ]

Enrollment: 634
Study Start Date: October 2004
Study Completion Date: July 2006
Primary Completion Date: July 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1 Drug: Tacrolimus
Other Name: Prograf, FK506
Experimental: 2 Drug: Tacrolimus
Other Name: Prograf, FK506

Detailed Description:
This phase III study shall provide detailed efficacy and safety information to compare this combination of sirolimus and tacrolimus with the current standard tacrolimus combination regimen (tacrolimus/MMF/steroids) which is widely used in European centres.

Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients between 18 and 60 years of age and having end stage kidney disease who will undergo primary renal transplantation or retransplantation are eligible for the study. Patients receiving a kidney transplant, from a cadaveric or living donor (not HLA identical) with compatible AB0 blood type can be included.

Exclusion Criteria:

  • Patient has a high immunological risk
  • Cold ischemia time greater than 30 hours
  • Patient has significant liver disease
  • Patient has severe hypercholesterolaemia
  • Patient is allergic or intolerant to study medication
  • Patient requires ongoing dosing with corticosteroids.
  • Patient or donor is known to be HIV positive
  • Patient with malignancy or history of malignancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00296361

  Show 59 Study Locations
Sponsors and Collaborators
Astellas Pharma Inc
Study Director: Medical Physician Astellas Pharma Europe B.V.
  More Information

Additional Information:
Responsible Party: Astellas Pharma Inc Identifier: NCT00296361     History of Changes
Other Study ID Numbers: FG-506-02-40
Study First Received: February 23, 2006
Last Updated: August 28, 2014

Keywords provided by Astellas Pharma Inc:
Kidney Transplantation
Treatment Outcomes

Additional relevant MeSH terms:
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Calcineurin Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antineoplastic Agents
Antifungal Agents processed this record on September 21, 2017